US private equity firm Bain Capital has agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit Mitsubishi Tanabe Pharma in a deal valued at approximately Y510bn ($3.3bn). The ...

TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ...

Bain Capital is making its latest biotech bid in Japan, where it plans to acquire Mitsubishi Tanabe Pharma Corp. The Boston-based private investment firm is buying Tanabe Pharma from Mitsubishi ...

TOKYO, Feb 7 (Reuters) - U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), saying it was encouraged by prospects of ...

US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), setting up one of the largest private equity buyouts in Japan's healthcare ...

Bain Capital has agreed to acquire Mitsubishi ... The U.S. investment company said Friday that it will buy Mitsubishi Tanabe Pharma for about 510 billion yen, equivalent to $3.37 billion.

Bain Capital’s buyout of Mitsubishi Tanabe Pharma brings a company with a drug portfolio and pipeline in areas such as immunology, central nervous system disorders, and metabolic disease.

Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit, adding to a dealmaking boom in Japan. The deal values Mitsubishi Tanabe Pharma at about ¥510 ...

Mitsubishi Chemical 4188-4.18%decrease; red down pointing triangle Group has agreed to sell its pharmaceutical business to Bain Capital for ... sell unit Mitsubishi Tanabe Pharma to the U.S ...

On February 7, 2025, Bain Capital announced a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (MTPC) from Mitsubishi Chemical Group Corporation in a carve-out transaction valued ...